The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Benefit-risk evaluation of ziv-aflibercept in combination with irinotecan-fluoropyrimidine-based chemotherapy (FOLFIRI) from the VELOUR trial using multicriteria decision analysis (MCDA).
Teresa Macarulla
No relevant relationships to disclose
Jasmanda Wu
Employment or Leadership Position - Sanofi
Larry Phillips
No relevant relationships to disclose
Sheikh Usman Iqbal
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Chris Kripas
Employment or Leadership Position - Sanofi
Zheng Gu
Employment or Leadership Position - Sanofi
Amy Freedman
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Pankaj Bhargava
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Eric Van Cutsem
Research Funding - Sanofi